Friday, July 10, 2026

Drug profile · INN

cariprazine

cariprazine (REAGILA) is a dopamine d3 receptor modulator.

EMA: approved TGA: approved NMPA: clinical trials Nervous system (N05) N05AX15
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — cariprazine
Class
Nervous system (N05)
Route
Patents
0
Programs
5
Data quality
0.83

Quick answer

cariprazine (REAGILA) is a dopamine d3 receptor modulator.

Key facts

INN cariprazine
Brand REAGILA
Mechanism Dopamine D3 receptor modulator
Therapeutic class Nervous system (N05)
ATC code N05AX15

Mechanism of action

Dopamine D3 receptor modulator

Approval history

Authority Status Date
EMA approved
TGA approved
NMPA clinical trials

Pipeline programs

  1. Cariprazine Phase 3 · AbbVie · Bipolar I Disorder
  2. RGH-188-203 Phase 3 · Gedeon Richter · Adolescent patient (13-17 years of age) with Schizophrenia
  3. RGH-MD-20 Phase 3 · Gedeon Richter · Adolescent Patients (13 to 17 years of age) with Schizophren
  4. Cariprazine Oral Capsule [Vraylar] Phase 2 · BRIGHT MINDS BIOSCIENCES · Cocaine Use Disorder
  5. INTENSIFY SZ Approved · Disc Medicine · schizophrenia, schizoaffective disorder, schizophrenifom dis

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Frequently asked questions

What is cariprazine?

cariprazine (REAGILA) is a dopamine d3 receptor modulator.

What is the brand name for cariprazine?

REAGILA is a marketed brand name for cariprazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.